Heart failure (HF), a leading global cause of mortality, affects over 64 million people worldwide, with rising prevalence driven by aging populations and increasing comorbidities. Based on left ventricular ejection fraction (LVEF), HF is classified into two primary subtypes: HF with reduced ejection fraction (HFrEF; LVEF <40%), which is characterized by impaired systolic contraction, frequently secondary to ischemic injury; and HF with preserved ejection fraction (HFpEF; LVEF ≥50%), which is defined by diastolic dysfunction with ventricular stiffness, predominantly linked to hypertension, metabolic disorders, and aging. 

Hypertrophic cardiomyopathy (HCM), a genetic disorder causing pathological left ventricular hypertrophy and diastolic impairment, represents a significant etiological contributor to both HF subtypes, particularly HFpEF.

In this webinar, GemPharmatech’s Dr. Qi Xiao will introduce diverse preclinical models developed for different applications in acceleration of therapeutic discovery. 

Webinar Topics include:

• Briefly summarize emerging therapies and diagnostic strategies in HF management

• Characterize paralogues of HFpEF and HFrEF

• Evaluate preclinical model systems for heart failure research, including Chronic HFrEF, Pressure-Overload HFrEF, Ischemic HFrEF and Cardiometabolic HFpEF

• Introduce genetic models of HCM, including Mybpc3 knockout model and Myh6 R403Q knock-in model

• Discover the integrated Cardiovascular Discovery Platform at GemPharmatech, explore our advanced phenotyping and customized model generation capabilities

Time:

Tuesday, May 27, 2025

8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST